CD19 and leukemia: However, the anti-tumor efficacy is limited by the transiently expressed CAR on the RNA-electroporated T cells compared with lenti- or retrovirally CAR-transduced T cells.7, 8, 25 In this study, we found that treating Nalm6 leukemia with REP T cells that were transferred with a blinatumomab RNA significantly prolonged the survival of the treated mice, results comparable to our observations in the same mouse model treated with CD19 CAR lentivirally transduced T cells.